Search

Displaying results 5771 - 5780 of 10000 in total
  1. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  2. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    These compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase). … The most commonly utilized bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  3. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  4. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  5. Drug

    Valproate bismuth

    go.drugbank.com/drugs/DB13910
    Approved

    Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

  6. Drug

    Daidzein

    go.drugbank.com/drugs/DB13182
    Investigational

    Categories: Topoisomerase II Inhibitors
  7. Drug

    Lorajmine

    go.drugbank.com/drugs/DB13651
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  8. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

    Synonyms: -PHENYLBENZYL)OXY)-N,N-DIMETHYLETHYLAMINE, ETHENAMINE, 2-(1-(4-CHLOROPHENYL)-1-PHENYLETHOXY)-N,N-DIMETHYL-
  9. Drug

    Empasiprubart

    go.drugbank.com/drugs/DB16469
    Investigational

    Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.[L50783]

  10. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.